Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 4/20 | 0.47 |
| ▸ | EDNRA | P25101 | 4/20 | 0.44 |
| ▸ | EDNRB | P24530 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5162772 | 0.91 | MAPK8 (0.45) | MAPK8EDNRAEDNRBL3MBTL1TP53 | |
| SCHEMBL4592238 | 0.90 | MAPK8 (0.44) | MAPK8EDNRAEDNRBL3MBTL1TP53 | |
| SCHEMBL4600089 | 0.89 | MAPK8 (0.44) | MAPK8EDNRAEDNRBL3MBTL1TP53 | |
| SCHEMBL5427868 | 0.88 | MAPK8 (0.43) | MAPK8EDNRAEDNRBL3MBTL1TP53 | |
| SCHEMBL5157558 | 0.87 | MAPT (0.42) | MAPK8EDNRAEDNRBL3MBTL1TP53 | |
| SCHEMBL5157621 | 0.86 | MAPK8 (0.45) | MAPK8EDNRAEDNRBL3MBTL1TP53 | |
| SCHEMBL5174825 | 0.86 | MAPK8 (0.45) | MAPK8EDNRAEDNRBL3MBTL1MAPT | |
| SCHEMBL5423167 | 0.86 | MAPK8 (0.63) | MAPK8EDNRAEDNRBTP53 | |
| SCHEMBL4591041 | 0.85 | MAPK8 (0.44) | MAPK8EDNRAEDNRBL3MBTL1TP53 | |
| SCHEMBL4592507 | 0.85 | MAPK8 (0.44) | MAPK8EDNRAEDNRBL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070248672-A1 | Indole and Azaindole Derivatives with Antitumor Action | NIKEM RESEARCH S.R.L. (IT) | 2007-10-25 | — | — | US | disclosed |
| EP-1750687-A2 | INDOLE AND AZAINDOLE DERIVATIVES WITH ANTITUMOR ACTION | NIKEM RESEARCH S.R.L. (IT) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005105213-A2 | INDOLE AND AZAINDOLE DERIVATIVES WITH ANTITUMOR ACTION | NIKEM RESEARCH S.R.L. (IT) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070248672-A1 | Indole and Azaindole Derivatives with Antitumor Action | IDO1, IDO2, INMT | MAPK8 4076/4885EDNRA 662/4885EDNRB 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.